Search Results - John Forster
- Showing 1 - 4 results of 4
-
1
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer by Harold J. Burstein, Anna Maria Storniolo, Sandra Franco, John Forster, S. Stein, S. D. Rubin, Vanessa Salazar, Kimberly Blackwell
Published 2008Artigo -
2
Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer by Anthony Fields, Alan Keller, Lee S. Schwartzberg, Stephen A. Bernard, Carl G. Kardinal, Alan F. Cohen, Joe Schulz, Peter D. Eisenberg, John Forster, Paul Wissel
Published 2009Artigo -
3
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens by Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu, Lee S. Schwartzberg, Michael Arbushites, Julie Maltzman, John Forster, S. D. Rubin, Steven H. Stein, Harold J. Burstein
Published 2009Artigo -
4
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer by Charles E. Geyer, John Forster, Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pieńkowski, Agnieszka Jagiełło-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark S. Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron
Published 2006Artigo
Search Tools:
Related Subjects
Cancer
Internal medicine
Medicine
Oncology
Adverse effect
Breast cancer
Chemotherapy
Lapatinib
Metastatic breast cancer
Trastuzumab
Colorectal cancer
Rash
Adjuvant therapy
Astrobiology
Biology
Capecitabine
Clinical endpoint
Clinical trial
Cohort
Combination therapy
Confidence interval
Fluorouracil
Gastroenterology
Hazard ratio
Interim analysis
Nausea
Paleontology
Physics
Progressive disease
Randomized controlled trial